Trials / Unknown
UnknownNCT02826044
The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy Volunteers
Pharmacokinetics,Safety and Tolerability Study Following Single and Multiple Dose of SP2086 in Healthy Volunteers
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
SP2086 is a novel inhibitor of Dipeptide base peptidase 4, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this single-dose and multiple-dose study the investigators evaluated the safety, tolerability and Pharmacokinetics profiles of SP2086 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SP2086 | The study has 3 doses groups and the 30 subjects were administrated SP2086 50mg,100mg,200mg respectively. |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2016-09-01
- First posted
- 2016-07-07
- Last updated
- 2016-07-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02826044. Inclusion in this directory is not an endorsement.